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Abstract 
 
Objective: The presence of unrecognized bipolar disorder or 
“bipolar spectrum” features has been suggested to contribute 
to poor treatment response in major depressive disorder. We 
aimed to investigate the association between putative bipolar 
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spectrum features and clinical outcomes in a cohort of 
fluoxetine-treated patients with MDD.  
Method: N= 602 outpatients aged 18-65 years with major 
depressive disorder recruited at 2 academic medical centers 
first entered a 12-week phase of open-label treatment with 
fluoxetine titrated up to 60mg/day. Patients who met the 
response criteria by week 12 entered the second phase of the 
study during which they were double-blindly randomized 
either to continue the same fluoxetine doses to which they had 
responded or to take placebo, for 52 weeks or until the 
occurrence of a relapse. The following clinical features 
suggestive of bipolar illness were selected for analysis: a 
history of early onset and recurrent depression, baseline 
atypical depressive features, irritability, psychoticism, 
suicidality, interpersonal sensitivity, comorbid anxiety 
disorders, and substance abuse/dependence. These measures 
were condensed into a summary score of bipolarity ranging 
from 0 to 10 points. We considered as primary outcomes time 
to response, remission, and discontinuation during acute 
treatment and time to relapse in the second phase of the study, 
utilizing survival analyses.  
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Results: Higher scores on the summary measure of bipolarity 
were not associated with differential acute treatment outcomes. 
They were significantly associated with a shorter time to 
relapse (p = 0.016). The median time until first recurrence was 
52.0 weeks in the group with lower scores vs. 12.0 wk in the 
group with higher scores.  
Conclusion:  Bipolar spectrum features may be associated with 
shorter time to recurrence in MDD patients after recovery, 
suggesting some predictive validity for this measure.  
 
 
Keywords: bipolar spectrum, major depressive disorder, 
treatment response, recurrence 
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INTRODUCTION 
The bipolar spectrum concept, which posits a 
symptomatologic continuum between major depression and 
bipolar disorder1-7, aims to recognize a hidden bipolar diathesis 
in depressed patients.  In clinical research, a long list of 
symptoms and/or psychopathological dimensions has been 
targeted as factors suited to distinguish individuals with 
unipolar depression from those at risk of developing a hypo-
/manic episode. Among the features of disease course and 
characteristics, an early age of onset8-11, a recurrent course of 
depression9-12 and a family history of bipolar disorder11,13 are 
consistently cited as indicators of ”bipolarity” in depressed 
subjects. Among individual symptoms, reported differences in 
the clinical presentation of unipolar depression versus bipolar 
depression are less reliable and less consistent. However, 
compared to unipolar depression, subjects with bipolar 
disorder have a higher prevalence in psychotic symptoms13-20, 
psychomotor disturbance/retardation13, 21, 22, intraepisode 
irritability, anger, agitation and restlessness23-27, mood 
lability28, 29, suicidality11, 30 and atypical features18, 24, 31-34 . 
Moreover, anxiety disorders and substance abuse/dependence 
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comorbidity have been more closely associated to bipolarity 
compared to unipolar depression35-42. 
  As antidepressants may be less effective in treating 
individuals with bipolar depression compared to those with 
major depressive disorder43-46, some authors suggest that 
unrecognized bipolar disorder contributes to apparent 
treatment resistance in individuals diagnosed with major 
depression47-49. To our knowledge, this has not yet been tested 
in large cohorts. Therefore, we constructed a summary 
measure of ten putative bipolar markers and hypothesized that 
higher scores on this measure would be associated with poorer 
treatment outcomes in depressed subjects. We examined a 
large cohort of fluoxetine-treated patients in which fluoxetine 
responders were randomized to continue fluoxetine or cross 
over to placebo.  
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Method 
The present study was conducted at the New York State 
Psychiatric Institute and the Depression Clinical and Research 
Program at Massachusetts General Hospital. The protocol was 
approved by the ethics committee at both sites, and all 
participants provided written informed consent. Patients 
eligible for inclusion were outpatients aged 18-65 years who 
met the Diagnostic and Statistical Manual of Mental Disorders, 
Third Edition-Text Revision (DSM-III-R) criteria for a current 
major depressive episode.  Diagnoses were confirmed by the 
Structured Clinical Interview for DSM-III-R Axis I 
Disorders—Patient Edition50.  It was not necessary that 
patients met any minimum score for severity of depressive 
symptoms in order to be included in the study. Exclusion 
criteria included pregnancy or breast-feeding; a significant risk 
of suicide; a lifetime history of any organic mental disorder, 
psychotic disorder, or mania; an unstable general medical 
condition, a history of seizures or of a neurological disorder 
that significantly affects central nervous system functioning; a 
history of substance abuse/dependence other than nicotine 
dependence in 6 months prior to enrollment; current 
consumption of medications that may induce or worsen 
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depression; clinical or laboratory evidence of hypothyroidism 
without adequate and stable replacement therapy; or a history 
of nonresponse to an adequate trial of a selective serotonin 
reuptake inhibitor (as defined by a 4-week trial of ≥40 mg of 
fluoxetine or the equivalent per day). 
The study consisted of two phases. After a 1-week medication-
free washout period, patients who still met inclusion criteria 
and had not significantly improved entered a 12-week phase of 
open-label treatment with fluoxetine. This phase included 
weekly treatment visits with a research psychiatrist for the first 
6 weeks, biweekly for the next 4 weeks, and two last visits for 
the remaining two weeks. Target fluoxetine doses were as 
follows: 10 mg/day for the first week, 20 mg/day for weeks 2–
4, 40 mg/day for weeks 4–8, and 60 mg/day for weeks 5–12. 
However, further dose adjustments were allowed based on 
tolerability. The primary research outcome was change in 17-
item Hamilton Depression Rating Scale (HAM-D) 51.  
 Patients whose HAM-D decreased by at least 50% by week 12 
were eligible to enter the second phase of the study, during 
which they were randomized either to continue the same 
fluoxetine treatment or start a similar dosing schedule of 
placebo. Fluoxetine and placebo capsules were matched in 
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size, shape, color, sheen, and texture to ensure blinding. Phase 
two continued for 52 weeks, or until the occurrence of a 
relapse. This second study period was divided according to 
convention, between a 6 month continuation phase and a 6 
month maintenance phase.  Treatment compliance was 
monitored by counting returned capsules at subsequent study 
visits; subjects who were deemed poor adherers by the treating 
study physician were dropped from the study. 
Summary Score Definition and Outcome Measures 
After reviewing the literature on indicators of “bipolarity” in 
depressed patients, three experienced clinicians (MF, RP, FC) 
selected clinical characteristics suggestive of a bipolar 
spectrum illness that could be assessed in this sample. 
Specifically, these characteristics included a history of early 
onset (≤ 21 years old), recurrent depression, baseline atypical 
depressive features, psychomotor retardation, irritability, 
psychoticism, suicidality, interpersonal sensitivity, current or 
past comorbid anxiety disorders, and past substance 
abuse/dependence (family history of bipolar disorder was not 
collected and so could not be included). These measures were 
condensed into a summary score ranging from 0 to 10 points. 
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Higher scores on the summary measure would indicate higher 
suspicion of bipolarity. 
Assessment procedures 
Diagnoses of major depression, current or lifetime anxiety or 
eating disorders and past substance use (current substance use 
was ruled out before enrollment) were established using the 
Structured Clinical Interview for DSM-III-R, clinician version 
(SCID-CV) 52. Subjects score one point on the summary 
measure if they present 2 or more anxiety or eating disorders 
from among Panic Disorder, Social Phobia, Obsessive-
Compulsive Disorder, Post-Traumatic Stress Disorder and 
Bulimia Nervosa. Subjects scored another point if they 
endorsed a history of at least 1 past substance 
abuse/dependence disorders among alcohol, cannabis, opioids, 
stimulants, cocaine and hallucinogens. Information about early 
onset of major depressive disorder (≤ 21), recurrent course, 
baseline atypical features and psychomotor retardation was 
also obtained from SCID. All available data from SCID and 
Beck Depression Inventory53, administered at baseline, were 
used to assign another point for history of suicide attempts 
and/or current ascertained suicidal ideation, plans or attempts. 
The Anger-Hostility section of the Symptom Questionnaire54, 
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the Massachusetts General Hospital Anger Attack 
Questionnaire55, and the Hostility Dimension of Symptom 
Check List-90 – SCL-9056 were used to determine the 
irritability component of the summary measure, with at least 
50% of items in one or more of these scales being necessary to 
warrant a point. 
We used the SCL-90 paranoid ideation and psychoticism 
subscales (at least 50% of items) and item 20 of the Hamilton 
Scale (≥ 2) to obtain a measure of psychoticism: while current 
overt psychosis (by SCID) was exclusionary per study 
protocol, presence of symptoms on SCL-90 or HAM-D was 
not. Finally, rating from the Interpersonal sensitivity 
Dimension of SCL-90, interpersonal sensitivity and rejection 
avoidance items from Columbia Atypical Depression 
Diagnostic Scale57 were adopted to evaluate the interpersonal 
sensitivity point in the summary score. 
Primary outcome measures included the time to response, 
remission, and discontinuation during acute treatment, as well 
as the time to relapse in the second phase of the study, utilizing 
survival analyses. Remission and response were defined 
respectively as a HAM-D-17 rating score ≤ 7 for at least 2 
consecutive weeks and as a reduction in baseline HAM-D-17 
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score by ≥ 50%. Relapse was defined as either having a HAM-
D-17 score of ≥ 14 or having met DSM-III-R criteria for major 
depression for at least 2 consecutive weeks. 
Statistical Methods 
Primary analysis excluded the subset of patients (N = 26) 
endorsing a lifetime diagnosis of bipolar II disorder, 
cyclothymia, or bipolar disorder NOS by the SCID criteria. 
However, scores in this subset were compared to the 
remainder of the sample in order to internally validate the 
summary measure of bipolarity.  
Based on sample mean and after visual inspection of 
distributions, for descriptive purposes we divided the summary 
measure in two levels, High and Low, depending on a score of 
≤ or > 4, respectively. Missing observations of the HAM-D 
scale were addressed using the Last Observation Carried 
Forward (LOCF) approach. We used Kaplan-Meier survival 
analyses to generate survival plots and estimate median time to 
response, remission, discontinuation and recurrence, with 
interquartile ranges (IQR). Cox regression model with Wald 
statistics was adopted to test the effect of the summary score 
on time to response, remission, discontinuation and relapse as 
dependent variables, adjusting for baseline depression severity 
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and for depression severity at time of randomization (e.g. 
entering phase II) for relapse. Where a main effect of the 
bipolarity score was identified we looked at treatment 
(fluoxetine vs placebo) for summary score (Low vs High) 
interaction.  
Summary data are reported using chi-square tests for 
categorical items and t-test for continuous variables, and 
displayed as proportions (percentages) and means with 
standard deviations respectively. Statistical tests of hypotheses 
were two-sided, with an alpha level of p≤0.05 and were 
performed with SPSS (Rel. 11.0.1. 2001. Chicago: SPSS Inc.) 
and STATA (Rel. 10. 2007. College Station, TX: StataCorp 
LP) for Windows. 
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Results 
Table 1 shows proportions of patients meeting criteria for each 
feature included in the summary measure; the most common 
was thoughts of suicide observed in 351 (55.7%) subjects at 
study entry. Overall, the mean score on this measure was 3.36 
(SD = 1.93); 180 subjects fell into the “High” category and 
448 into the “Low” category. As summarized in Table 2, the 
high group was more likely to be female, single and younger 
and to have a greater severity of depression at baseline. 
Notably, the mean score on the summary measure was 
significantly greater for the cohort (N = 26) with ascertained 
bipolarity excluded from following analyses in comparison 
with unipolar patients (N = 602) (Mean = 4.69; SD = 1.93 vs 
Mean = 3.30; SD = 1.57; t = 3.631 p = < 0.001). Survival 
analyses showed that a high score on the summary measure 
was not significantly associated with differential acute 
treatment outcomes, both in terms of time to response (HR = 
1.17, 95% CI = 0.92-1.48; p = 0.20) and remission (HR = 1.12, 
95% CI = 0.86-1.46; p = 0.39) (Fig.1), nor was it associated 
with time to treatment discontinuation for any reason (HR = 
0.94, 95% CI = 0.68-1.30; p = 0.71). However, High summary 
measure scores were significantly associated with a shorter 
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time to relapse (HR = 1.58, 95% CI = 1.09-2.28; p = 0.016) 
(Fig. 2). The median time until first recurrence was 52.0 weeks 
(IQR = 6- NC) in the group with lower scores compared to 
12.0 weeks (IQR = 4-NC) in the group with higher scores. 
Incorporating individual terms for age, sex, marital status, 
severity of depression at baseline and history of recurrences 
did not change the hazard ratio by more than 10%. Moreover, 
history of recurrence was a component of the measure, but was 
not itself significantly associated with hazard of relapse. 
 Notably, there was no significant treatment-by-group 
interaction (HR = 0.96, 95% CI = 0.58-1.61; p = 0.89), 
suggesting similar results in subjects on fluoxetine or placebo. 
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Discussion 
The primary finding of our analysis is the association of high 
scores on a summary measure of bipolarity with a shorter time 
to recurrence, but no difference in acute response. A high 
degree of recurrences was targeted as the core feature of 
bipolar illness by Kraepelin58. Consistent with our results, 
prior studies suggested that a higher susceptibility to 
recurrence is both a marker of bipolarity and an adverse 
outcome linked to soft bipolarity59-62. 
 Since antidepressants don’t work as well for bipolar 
depression as for unipolar depression44, 47-49, some authors 
argue that an underlying bipolar diathesis or a soft bipolar 
spectrum could explain treatment resistance in a large 
proportion of unipolar depressed subjects47, 49. Also, many 
concerns have been raised on the prescription of 
antidepressants for bipolar depression with many studies 
reporting an increased risk of hypo-/manic switches, mixed 
features and suicidality47, 63-67.  
Furthermore, antidepressant use in bipolar disorder has been 
associated with increased risk of relapses and cycle 
acceleration in the long term68-70 and the loss of an initial 
antidepressant response (i.e. “wear-off” effect) has been 
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demonstrated to be more common in bipolar than in unipolar 
depression71.   
Our results are partially consistent with these arguments. They 
suggest that the effect of greater bipolar loading is not on the 
acute antidepressant response, but rather on recurrence risk. 
Importantly, this effect is not due to a recurrent course, per se, 
because neither a history of recurrence nor other demographic 
and clinical variables seem to confound the hazard of relapse. 
Moreover, continuation of antidepressant treatment did not 
seem to mediate the association between summary measure of 
bipolarity and risk of relapses. However, a longer follow-up 
may be more appropriate to ascertain the impact of 
antidepressant on cycling.  
Of note, this analysis is not intended to address the important 
related issue of depressive mixed states and was not designed 
to measure intra-depressive hypo-/manic symptoms or mixed 
features such as agitation, crowded thoughts, or other 
intraepisode hypomanic symptoms. In this regard, 
intradepressive mixed features have been reported to be more 
common in bipolar I and II disorders than in unipolar 
depression, to be exacerbated by antidepressants and to have a 
correlation with a bipolar family history loading4, 23, 72-76. As a 
19 
 
result, this summary measure targets the presence of soft 
bipolarity in a sample of outpatients at low risk per se of 
bipolar illness.  
Limitations 
One of the main limitations of this study is that we were 
unable to include all putative predictors of “bipolarity,” such 
as family history of bipolar disorder, in the summary measure. 
Moreover, although we considered some psychopathological 
dimensions such as psychoticism, interpersonal 
sensitivity/rejection avoidance, and irritability/anger/hostility, 
many other personality traits or lifestyle aspects, such as 
neuroticism, introversion or extraversion, proneness to anxiety, 
distinct affective temperaments, number of divorces, 
sentimental turmoil, economic, geographical instability etc., 
have been claimed to discriminate unipolar from bipolar 
depressed subjects77, 78, but were not available in this dataset. 
Also, the summary score we propose assigns an equal weight 
to each characteristic assessed. We chose this approach 
because, to the best of our knowledge, there is no data 
suggesting the relative importance and individual value of 
non-manic bipolarity markers. Also, because our sample 
consisted only of outpatients treated with fluoxetine or 
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placebo, it is unclear if our findings are generalizable to other 
more severe population of patients needing hospitalization or 
receiving different medications. 
Conclusions 
Mood disorders are highly heterogeneous in their phenotypic 
expression and clinical course of illness79-81.  Because there are 
no pathognomonic characteristics of bipolar compared to 
unipolar depression, it is unlikely that only one symptom, 
cluster of symptoms, or course specifier can really help the 
clinician to make a differential diagnosis82. Our results suggest 
that a summary measure of bipolar spectrum features has some 
predictive validity in terms of recurrences. However, these 
results do not support the often cited notion that treatment-
resistant depression is likely to be bipolar depression. 
Replication will be necessary in order to extend and generalize 
our results. 
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Table 1. Clinical characteristics included in the summary 
 measure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 ≥ 2 current or lifetime disorders in comorbidity among: Panic Disorder, Social Phobia, Obsessive-
Compulsive Disorder, Post-Traumatic Stress Disorder, Bulimia 
2 
≥ 1 lifetime alcohol/substance abuse/dependence disorders (study protocol did not allow the inclusion of 
subjects with current alcohol/substance abuse/dependence comorbidity) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N % 
Early onset (age ≤ 21 years) 224 35.6 
Recurrent (> 1 episode) 222 35.2 
Atypical features 183 29.0 
Irritability/hostility/anger 258 41.0 
Psychoticism/Paranoid Ideation 238 37.8 
Thoughts of suicide 351 55.7 
Psychomotor retardation 135 21.4 
Anxiety/Bulimia1 55 8.7 
Alcohol/Substance Abuse/Dependence2 148 23.5 
Interpersonal sensitivity/rejection 
avoidance 
295 46.8 
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Table 2. Demographic and Baseline Characteristics 
   Low Index High Index   
Characteristic N/Mean %/SD N/Mean %/SD N/Mean %/SD χ2/ t p 
Sex         
  Female 341 54.1 229 51.1 112 62.2 6.25 0.01 
Age 37.36 11.44 38.44 11.55 34.70 10.72 3.74 <0.001 
Years of education 14.67 2.59 14.79 2.54 14.36 2.67 1.88 0.06 
Severity of 
depression: baseline 
17.44 5.13 17.02 4.91 18.36 5.49 2.87 0.004 
Severity of 
depression: time of 
randomization 
7.30 5.68 7.20 5.49 7.52 6.08 0.50 0.62 
Race         
  Caucasian 469 74.4 332 74.3 137 76.1 0.23 0.6 
Marital status         
  Single 371 58.9 249 55.8 122 67.8 7.58 0.006 
Employment status         
  Full time 292 46.3 212 47.6 80 44.7 0.45 0.5 
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Figure 1. Survival Curve of Time to Remission adjusted for baseline depression severity. Low vs High 
Index Scores. 
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Hazard ratio = 1.12 (95% CI = 0.86-1.46,  
p = 0.39) 
Median Low Index = 6.0 ( IQR = 10.0-4.0) 
Median High Index = 6.0 ( IQR =  10.0-3.0) 
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Figure 2. Survival Curve of Time to Recurrence adjusted for depression severity at time of 
randomization. Low  vs  High Index Scores. 
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Hazard ratio = 1.58 (95% CI = 1.09-2.28);  
p = 0.016 
Median Low Index = 52.0 (IQR = 6- NC) 
Median High Index = 12.0 (IQR = 4-NC) 
 
